BioLineRx to develop Compugen’s novel peptide drug candidates

BioLineRx (NASDAQ, TASE:BLRX) and Compugen (NASDAQ:CGEN) have entered into a collaboration agreement to develop and commercialize mutually selected Compugen-discovered drug candidates for the treatment of various diseases, ranging from acute and chronic inflammatory diseases through cardiac diseases, retinopathy and cancer. Under the accord, Compugen will provide promising drug candidates, primarily peptides, which were identified using [...]

Cellceutix’s potential breakthrough in cancer research

Cellceutix (OTCBB:CTIX) of Beverly, Mass. believes it has found the Holy Grail in cancer research: a compound that activates a tumor suppressor protein known as p53, long regarded as possibly holding the key to future cancer therapies. “Our Kevetrin drug reactivates p53 to its normal function of dictating whether to fix the cell or kill [...]

In conversation with Michael King and Elemer Piros

Rodman & Renshaw’s 13th Annual Healthcare Conference last week was another roaring success. Held in conjunction with Rodman’s Annual Global Investment Conference, total attendees reached some 4,000, with 400 presenting companies from the healthcare, mining, energy, financial services and clean technology sectors, Israel and China. In this exclusive interview with BioTuesdays.com, two of Rodman’s managing [...]

Enzo reports on key discovery of novel targets

Scientists from Enzo Biochem’s (NYSE:ENZ) therapeutics group have presented a podium session entitled The Presence of Sulfated Tyrosine In Scelerostin and Dkk1 Ligands and its Effect on Wnt Signaling at the WNT 2011 conference in Los Angeles. “Our scientific team has identified a new target on a key modulator of the Wnt system that not [...]

In conversation with Simon Chin

As CEO and founder of Iris BioTechnologies (OTCBB:IRSB), Simon Chin has been a poster boy for personalized medicine. The former founder and CEO of DNA Laboratories, where he developed key DNA chip technologies, Mr. Chin admits to an epiphany back in 1999 when he realized the information from the Human Genome project would fundamentally change [...]

Bringing sunshine to cancer patients

After many pharma and biotech disappointments using vitamin D in oncology, Receptor Therapeutics may be on the precipice of bringing sunshine to cancer patients. All it needs is the money to begin clinical development. “Many experts contend that about half the human population is deficient in vitamin D,” CEO Dr. Joseph Elliot says in an [...]

Shrew saliva may detect and treat cancer

Paralytic venom in the saliva of the tiny North American short-tailed shrew, which hunts its prey on the forest floor, may hold the key to a diagnostic and therapeutic treatment for ovarian, breast and prostate cancers. “We found out that the paralytic agent in the venom was a peptide material that we eventually named soricidin,” [...]

Critical Outcome MOA on COTI-2

Critical Outcome Technologies (TSX-V:COT) for the first time has outlined the specific cellular target and mechanism of action for its lead oncology candidate COTI-2. “We have now demonstrated through a series of key experiments that the Pleckstrin Homology domain of (the protein) AKT/AKT2 is a selective cellular target for COTI-2,” Critical Outcome president Dr. Wayne [...]

Oncolytics gets rights to potential cancer drug

Oncolytics Biotech (TSX: ONC; NASDAQ: ONCY) of Calgary has swung a deal for a stake in closely-held British Canadian Biosciences, including potential rights to purchase BCB’s oncology product, which  is entering Phase 2 studies to treat solid tumours. Under the accord, Oncolytics purchased all of the convertible preferred shares of BCB in exchange for 200,000 common [...]